CY1106746T1 - Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης - Google Patents

Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης

Info

Publication number
CY1106746T1
CY1106746T1 CY20071100964T CY071100964T CY1106746T1 CY 1106746 T1 CY1106746 T1 CY 1106746T1 CY 20071100964 T CY20071100964 T CY 20071100964T CY 071100964 T CY071100964 T CY 071100964T CY 1106746 T1 CY1106746 T1 CY 1106746T1
Authority
CY
Cyprus
Prior art keywords
pulmonary hypertension
irbesartan
prevention
treatment
directed
Prior art date
Application number
CY20071100964T
Other languages
English (en)
Inventor
Sylvie Cosnier-Pucheu
Dino Nisato
Alain Roccon
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1106746T1 publication Critical patent/CY1106746T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση έχει ως αντικείμενο την χρήση του irbesartan για την παρασκευή χρήσιμων σκευασμάτων τα οποία απευθύνονται στην πρόληψη ή την θεραπεία της αρτηριακής πνευμονικής υπέρτασης ή της πνευμονικής υπέρτασης.
CY20071100964T 2001-10-26 2007-07-19 Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης CY1106746T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
CY1106746T1 true CY1106746T1 (el) 2012-05-23

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100964T CY1106746T1 (el) 2001-10-26 2007-07-19 Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης

Country Status (24)

Country Link
US (2) US20040242567A1 (el)
EP (1) EP1441723B1 (el)
JP (1) JP4542777B2 (el)
CN (1) CN100418526C (el)
AT (1) ATE361071T1 (el)
AU (1) AU2002350832B2 (el)
BR (1) BR0213479A (el)
CA (1) CA2461625C (el)
CY (1) CY1106746T1 (el)
DE (1) DE60219940T2 (el)
DK (1) DK1441723T3 (el)
EA (1) EA007952B1 (el)
ES (1) ES2286304T3 (el)
FR (1) FR2831446B1 (el)
HU (1) HUP0401633A3 (el)
IL (2) IL161116A0 (el)
IS (1) IS2849B (el)
MX (1) MXPA04003910A (el)
NO (1) NO332313B1 (el)
NZ (1) NZ532130A (el)
PL (1) PL209263B1 (el)
PT (1) PT1441723E (el)
WO (1) WO2003035062A1 (el)
ZA (1) ZA200402696B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP4313024A1 (en) * 2021-03-23 2024-02-07 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
EP1106210A3 (en) 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
HUP0401633A3 (en) 2009-06-29
US20090247510A1 (en) 2009-10-01
IL161116A (en) 2010-12-30
FR2831446B1 (fr) 2004-03-05
CA2461625A1 (en) 2003-05-01
CA2461625C (en) 2011-07-05
NO20041732L (no) 2004-07-23
PT1441723E (pt) 2007-07-26
PL368737A1 (en) 2005-04-04
NZ532130A (en) 2006-10-27
BR0213479A (pt) 2004-11-03
ZA200402696B (en) 2005-06-29
WO2003035062A1 (fr) 2003-05-01
ATE361071T1 (de) 2007-05-15
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
CN100418526C (zh) 2008-09-17
HUP0401633A2 (hu) 2004-12-28
ES2286304T3 (es) 2007-12-01
DE60219940D1 (de) 2007-06-14
JP2005506369A (ja) 2005-03-03
IL161116A0 (en) 2004-08-31
AU2002350832B2 (en) 2006-11-30
DE60219940T2 (de) 2008-01-17
FR2831446A1 (fr) 2003-05-02
EA007952B1 (ru) 2007-02-27
IS7200A (is) 2004-03-29
US8088827B2 (en) 2012-01-03
EP1441723A1 (fr) 2004-08-04
EP1441723B1 (fr) 2007-05-02
IS2849B (is) 2013-09-15
PL209263B1 (pl) 2011-08-31
JP4542777B2 (ja) 2010-09-15
MXPA04003910A (es) 2004-07-23
CN1610548A (zh) 2005-04-27
US20040242567A1 (en) 2004-12-02
NO332313B1 (no) 2012-08-27

Similar Documents

Publication Publication Date Title
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
FR17C0003I2 (fr) Steroides comme agonistes de fxr
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1114024T1 (el) Ενωσεις που αναστελλουν τη φλεγμονη
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105915T1 (el) Παραγωγα θειαζολιου για τη θepαπεια των παθησεων που σχετιζονται με τους ppar
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
DK1250337T3 (da) Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
DK1276495T3 (da) Anvendelse af rekombinante lungesurfactant-præparater til tidlig behandling af akutte lungesygdomme
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
DE60203026D1 (de) Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden
CY1105987T1 (el) Παραγωγα πυριδινο-2-υλο-μεθυλαμινης για την θepαπεια της εξαρτησης απο τα οπιοειδη
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE328883T1 (de) Imidazopyridin-8-one
ATE324887T1 (de) Citalopram zur behandlung von bluthochdruck
DE60209709D1 (de) Verfahren zur herstellung von chinazolinen